

DAFTAR PUSTAKA

Agarwal, A.K., Raja, A., dan Brown, B.D., 2023, Chronic Obstructive Pulmonary Disease, <https://www.ncbi.nlm.nih.gov/books/NBK559281/>, diakses pada 30 September 2023.

Alqahtani, J.S., Aldabayan, Y.S., Aldharir, A.M., Rajeh, A.M.A., Mandal, S., dan Hurst, J.R., 2021, Predictors of 30-and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study, *International Journal of Chronic Obstructive Pulmonary Disease*, 16: 2769–2781.

Andréanne, G., Geneviève, C., & Claude, P. (2011). Prevalence of dyspepsia in COPD patients: Experience in a large Canadian cohort. *European Respiratory Journal*, 38(Suppl 55). https://erj.ersjournals.com/content/38/Suppl_55/p3480.article-info

Arnaout, A. Y., Alhejazi, T. J., Nerabani, Y., Hamdan, O., Arnaout, K., Arnaout, I., & aljarad, Z. (2023). The prevalence and risk factors of functional dyspepsia among adults in low- and middle-income countries: An international cross-sectional study. *Medicine*, 102(40), e35437. <https://doi.org/10.1097/md.00000000000035437>

Baize, P., Kohman, K., Stoffel, J., & Weigartz, K. (2021). 826: Albuterol Versus Terbutaline in Emergency Department Management of Asthma or COPD Exacerbation. *Critical Care Medicine*, 49(1), 410–410. <https://doi.org/10.1097/01.ccm.0000729192.37526.b9>

Barr, R. G., Rowe, B. H., & Camargo, C. A., Jr (2003). Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. *BMJ (Clinical research ed.)*, 327(7416), 643. <https://doi.org/10.1136/bmj.327.7416.643>

Barnes, P.J., 2010, Inhaled Corticosteroids, *Pharmaceuticals (Basel)*, Vol.3, No.3, Hal : 514 – 540.

Barnes, P.J., 2016, Sex Differences in Chronic Obstructive Pulmonary Disease Mechanism, *American Journal of Respiratory and Critical Care Medicine*, Vol : 193, No.8, Hal : 813 – 824.

Boersma, W.G., 2012, Antibiotics in Acute Exacerbation of COPD: The Good, The Bad and The Ugly, *European Reaspiratory Journal*, Vol. 40, No.1, Hal : 1 – 3.

Boixeda, R., Bacca, S., Elias, L., Capdevila, J. A., Vilà, X., Mauri, M., & Almirall, J. (2014). Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD. *Archivos de bronconeumologia*, 50(12), 514–520. <https://doi.org/10.1016/j.arbres.2014.02.001>

Bourbeau, J., Seden, M. F., Metz, K., Li, P. Z., & Pinto, L. (2016). Early COPD Exacerbation Treatment with Combination of ICS and LABA for Patients Presenting with Mild-to-Moderate Worsening of Dyspnea. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 13(4), 439–447. <https://doi.org/10.3109/15412555.2015.1101435>

Caughey, G. E., Preiss, A. K., Vitry, A. I., Gilbert, A. L., & Roughead, E. E. (2013). Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. *Diabetes care*, 36(10), 3009–3014. <https://doi.org/10.2337/dc12-2197>

Cazzola, M., dan Matera, M.G., Triple Combination in Chronic Obstructive Pulmonary Disease – Is Three Better Than Two?, Vol. 15, No. 17, Hal : 2475 – 2478.

Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N. A., & Matera, M. G. (2017). Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 14(5), 552–563. <https://doi.org/10.1080/15412555.2017.1347918>

Celli, B. R., & Barnes, P. J. (2007). Exacerbations of chronic obstructive pulmonary disease. *European Respiratory Journal*, 29(6), 1224–1238. <https://doi.org/10.1183/09031936.00109906>

Chiu, Y.C., Chang, W.P., Tang, G.J., Lan, T.Y., Lee, K.Y., dan Su, V.Y.F., 2022, Chronic Obstructive Pulmonary Disease is Associated with Higher Risk of Functional Gastrointestinal Disorder, <https://pubmed.ncbi.nlm.nih.gov/35427844/>, diakses pada 06 Januari 2024.

Dhamane, A. D., Moretz, C., Zhou, Y., Burslem, K., Saverno, K., Jain, G., Renda, A., & Kaila, S. (2015). COPD exacerbation frequency and its association with health care resource utilization and costs. *International journal of chronic obstructive pulmonary disease*, 10, 2609–2618. <https://doi.org/10.2147/COPD.S90148>

Dipiro, J. T., Yee, G. C., Posey, L. M., 2020, *Pharmacotherapy A Pathophysiologic Approach Eleventh Edition*, McGraw-Hill Professional, New York.

Dong, H., Hao, Y., Li, D., Su, Z., Li, W., Shi, B., & Gao, P. (2020). Risk Factors for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Industrial Regions of China: A Multicenter Cross-Sectional Study. *International journal of chronic obstructive pulmonary disease*, 15, 2249–2256. <https://doi.org/10.2147/COPD.S270729>

Donohue, J. F. (2005). Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects. *Proceedings of the American Thoracic Society*, 2(4), 272–281. <https://doi.org/10.1513/pats.200505-047sr>

Egbonu, F., Antonio, F. A., & Edavalath, M. (2014). Effect of inhaled corticosteroids on glycemic status. *The open respiratory medicine journal*, 8, 101–105. <https://doi.org/10.2174/1874306401408010101>

Ek, A., Larsson, K., Siljerud, S., dan Palmberg, L., 1999. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. *Allergy*, 54: 691–699.

Giezeman, M., Sundh, J., Athlin, Å., Lisspers, K., Stållberg, B., Janson, C., Montgomery, S., Kisiel, M. A., Nager, A., Sandelowsky, H., & Hasselgren, M. (2023). Comorbid Heart Disease in Patients with COPD is Associated with Increased Hospitalization and Mortality - A 15-Year Follow-Up. *International journal of chronic obstructive pulmonary disease*, 18, 11–21. <https://doi.org/10.2147/COPD.S378979>

Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020, *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2023 Report)*, <http://www.goldcopd.org>, diakses pada Oktober 2022.

Goel, M. K., Khanna, P., & Kishore, J. (2010). Understanding survival analysis: Kaplan-Meier estimate. *International journal of Ayurveda research*, 1(4), 274–278. <https://doi.org/10.4103/0974-7788.76794>

Halpin, D.M.G., Gray, J., Edwards, S.J., Morais, J., dan Singh, D., 2011, Budesonide/Formoterol vs Salmeterol/Fluticasone in COPD: a Systematic Review and Adjusted Indirect Comparison of Pneumonia in Randomised Controlled Trials, *The International Journal of Clinical Practice*, Vol. 65, No. 7, Hal : 764 – 774.

Hanania, N.A., Crater, G.D., Morris, A.N., Emmett, A.H., O'Dell, D.M., dan Niewoehner, D.E., 2012, Benefits of Adding Fluticasone propionate/Salmeterol to Tiotropium in Moderate to Severe COPD, *Respiratory Medicine*, Vol. 106, No.1, Hal : 91 – 101.

Harlan, J., 2017, *Analisis Survival*, Gunadarma, Indonesia.

Huang, K., Guo, Y., Kang, J., An, L., Zheng, Z., Ma, L., Peng, L., Wang, H., Su, R., Itoh, Y., & Wang, C. (2019). The Efficacy Of Adding Budesonide/Formoterol To Ipratropium Plus Theophylline In Managing Severe Chronic Obstructive Pulmonary Disease: An Open-Label, Randomized Study In China, *Therapeutic Advances in Respiratory Disease*, Vol. 13 : 1 – 13 <https://doi.org/10.1177/1753466619853500>

Hwa, J.C., Bae, K.J., Hyun, P.Y., Iseul, Y., Jeong, S.L., Kyu, M.L., Ha, K.S., Yeon, L.W., Joong, Y.S., dan Ho, L.J., 2021, Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study, *International Journal of Chronic Obstructive Pulmonary Disease*, Vol. 2021, No. 16, Halaman : 3229 – 3237.

Jain N. K. (2017). Chronic obstructive pulmonary disease and tuberculosis. *Lung India : official organ of Indian Chest Society*, 34(5), 468–469. https://doi.org/10.4103/lungindia.lungindia_183_17

Jakimova, M.A., Karpina, N., Gordeeva, O., dan Asanov, R., 2019, Comorbidity: Pulmonary Tuberculosis and Chronic Obstructive Pulmonary Disease, *European Respiratory Journal*, Vol : 54, No.63 : PA2969 10.1183/13993003.congress-2019.PA2969

Ji, Z., Hernández Vázquez, J., Bellón Cano, J. M., Gallo González, V., Recio Moreno, B., Cerezo Lajas, A., Puente Maestu, L., & de Miguel Díez, J. (2020). Influence of Pneumonia on the Survival of Patients with COPD. *Journal of clinical medicine*, 9(1), 230. <https://doi.org/10.3390/jcm9010230>

Jones, P. W., Agusti, A. G. N., 2006, Outcomes and Markers In The Assessment Of Chronic Obstructive Pulmonary Disease, *European Respiratory Journal*, 27: 822-832.

Kemenkes RI, 2019, *Pedoman Nasional Pelayanan Kedokteran Tataaksana Penyakit Paru Obstruktif Kronik*, Kementerian Kesehatan Republik Indonesia, Jakarta.

Khamitov, R., & Aigoul Zinnatullina. (2021). Study of gastroesophageal reflux disease in frequent exacerbations of chronic obstructive pulmonary disease. *European Respiratory Journal*, 58(65). <https://doi.org/10.1183/13993003.congress-2021.pa2225>

Kilic, H., Kokturk, N., Sari, G., & Cakır, M. (2015). Do females behave differently in COPD exacerbation?. *International journal of chronic obstructive pulmonary disease*, 10, 823–830. <https://doi.org/10.2147/COPD.S78952>

Kim, J., Lee, J.H., Kim, Y., Kim, K., Oh, Y.M., Yoo, K.H., Rhee, C.K., Yoon, H.K., Kim, Y.S., Park, Y.B., Lee, S.W., dan Lee, S.D., 2013, Associated Between Chronic Obstructive Pulmonary Disease and Gastroesophageal Reflux Disease: a National Cross-Sectional Cohort Study, *BMC Pulmonary Medicine*, Vol. 13, No. 51, Hal : 1 – 10.

Kim, S. H., Park, J. H., Lee, J. K., Heo, E. Y., Kim, D. K., & Chung, H. S. (2017). Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. *Medicine*, 96(19), e6826. <https://doi.org/10.1097/MD.00000000000006826>

Knorst, M., Nunes, J., Ries, L., Valentini, J., dan Rech, L., 2011, Association Between Comorbidities, Disease Severity and Body Mass Index in COPD Patients, *European Respiratory Journal*, Vol. 38, No.55 : p3574 https://erj.ersjournals.com/content/38/Suppl_55/p3574

Kristiningrum, E., 2019, Farmakoterapi Penyakit Paru Obstruktif Kronis (PPOK), *CDK 275*, Volume 43, No.4, Hal: 262 – 271.

Kopsaftis, Z. A., Sulaiman, N. S., Mountain, O. D., Carson-Chahhoud, K. V., Phillips, P. A., & Smith, B. J. (2018). Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review. *Systematic reviews*, 7(1), 213. <https://doi.org/10.1186/s13643-018-0860-0>

Lahousse, L., 2021, Personalizing Oral Corticosteroid Dose in Severe COPD Exacerbation, *Chest Journal*, Vol. 160, No. 5, Hal : 1581 – 1582.

Larsson, K., Janson, C., Lisspers, K., Jørgensen, L., Stratelis, G., Telg, G., dkk., 2013. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. *Journal of Internal Medicine*, 273: 584–594.

Lee, A. L., & Goldstein, R. S. (2015). Gastroesophageal reflux disease in COPD: links and risks. *International journal of chronic obstructive pulmonary disease*, 10, 1935–1949. <https://doi.org/10.2147/COPD.S77562>

Lee, H.W., Park, J., Jo, J., Jang, E.J., dan Lee, C.H., 2019, Comparison of Exacerbation and Mortality Among Regular Inhaled Therapies for Patients with Stable Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis, *PLoS Med* 16(11): e1002958. <https://doi.org/10.1371/journal.pmed.1002958>

Li Z. (2021). The effect of adjuvant therapy with ambroxol hydrochloride in elderly chronic obstructive pulmonary disease patients. *American journal of translational research*, 13(8), 9285–929

Mahishale, V., Mahishale, A., Patil, B., Sindhuri, A., & Eti, A. (2015). Screening for diabetes mellitus in patients with chronic obstructive pulmonary disease in tertiary care hospital in India. *Nigerian medical journal : journal of the Nigeria Medical Association*, 56(2), 122–125. <https://doi.org/10.4103/0300-1652.150699>

Manian, P., 2019, Chronic Obstructive Pulmonary Disease Classification, Phenotypes and Risk Assessment, *Journal of Thoracic Disease*, Vol 11, No. 14, Hal: S1761 – S1766.

Mara, Y.A., 2023, Pengaruh Penggunaan Flutikason/Salmeterol dibandingkan Budesonid/Formoterol Terhadap Kejadian Pneumonia Pada Pasien Penyakit Paru Obstruktif Kronis di RSUP Dr. Sardjito Yogyakarta, *Tesis*, Universitas Gadjah Mada, Yogyakarta.

Maselli, D. J., & Hanania, N. A. (2018). Asthma COPD overlap: Impact of associated comorbidities. *Pulmonary Pharmacology & Therapeutics*, 52, 27–31. <https://doi.org/10.1016/j.pupt.2018.08.006>

Matera, M. G., Hanania, N. A., Maniscalco, M., & Cazzola, M. (2023). Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities. *Drugs & Aging*, 40(7), 605–619. <https://doi.org/10.1007/s40266-023-01038-0>

McNee, W., 2016, Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease?, *Annals of The American Thoracic Society*, Vol. 13, No. 5, Hal: S429 – S437.

National Heart, Lung, and Blood Institute, 2022, COPD Diagnosis, <https://www.nhlbi.nih.gov/health/copd/diagnosis> diakses pada 19 September 2023.

Niu, Y., Xing, Y., Li, J., Shui, W., Gu, Y., Zhang, C., & Du, H. (2021). Effect of Community-Acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 18(4), 417–424. <https://doi.org/10.1080/15412555.2021.1950664>

Nuttall F. Q. (2015). Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutrition today*, 50(3), 117–128. <https://doi.org/10.1097/NT.0000000000000092>

Ohbayashi, H., & Adachi, M. (2012). Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD. *International journal of general medicine*, 5, 517–524. <https://doi.org/10.2147/IJGM.S20833>

Oldroyd, S. H., & Bhardwaj, A. (2022). *Pulmonary Hypertension*. *PubMed;StatPearls Publishing*. <https://www.ncbi.nlm.nih.gov/books/NBK482463/>

Pandey, N., & Cascella, M., 2023, *Beta Lactam Antibiotics*. National Library of Medicine; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK545311/>

Pangaribuan, M., Yunus, F., Damayanti, T., dan Rochsismandoko, 2020, Prevalens Diabetes Melitus Pada Pasien Penyakit Paru Obstruktif Kronik, *Jurnal Respirologi Indonesia*, Vol.40, No.1, Hal : 43 – 52.

Papadopoulou, E., Hansel, J., Lazar, Z., Kostikas, K., Tryfon, S., Vestbo, J., & Mathioudakis, A. G. (2023). Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. *European Respiratory Review*, 32(167), 220141. <https://doi.org/10.1183/16000617.0141-2022>

Papi, A., Avdeev, S., Calverley, P. M. A., Cordeiro, C. R., Jesenak, M., Koblížek, V., Petkova, D., Rogliani, P., Tarraf, H., Tzanakis, N., Ulmeanu, R., Uzaslan, E., & Adir, Y. (2020). Use of mucolytics in COPD: A Delphi consensus study. *Respiratory Medicine*, 175, 106190. <https://doi.org/10.1016/j.rmed.2020.106190>

Patel, A. R. C., Donaldson, G. C., Mackay, A. J., Wedzicha, J. A., & Hurst, J. R. (2012). The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. *Chest*, 141(4), 851–857. <https://doi.org/10.1378/chest.11-0853>

Peltola, L., Päätsi, H., & Harju, T. (2020). COPD Comorbidities Predict High Mortality – Asthma-COPD-Overlap Has Better Prognosis. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 17(4), 366–372. <https://doi.org/10.1080/15412555.2020.1783647>

Perez, T. A., Castillo, E. G., Ancochea, J., Pastor Sanz, M. T., Almagro, P., Martínez-Camblor, P., Miravittles, M., Rodríguez-Carballeira, M., Navarro, A., Lamprecht, B., Ramírez-García Luna, A. S., Kaiser, B., Alfageme, I., Casanova, C., Esteban, C., Soler-Cataluña, J. J., De-Torres, J. P., Celli, B. R., Marin, J. M., & Lopez-Campos, J. L. (2020). Sex differences between women and men with COPD: A new analysis of the 3CIA study. *Respiratory Medicine*, 171, 106105. <https://doi.org/10.1016/j.rmed.2020.106105>

Perrone, V., Sangiorgi, D., Buda, S., & Degli Esposti, L. (2016). Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. *International journal of chronic obstructive pulmonary disease*, 11, 2749–2755. <https://doi.org/10.2147/COPD.S114554>

Poole, P. J., 2006, Role of Mucolytics in the Management of COPD, *International Journal of Chronic Obstructive Pulmonary Disease*, Vol 1, No.2, Halaman : 123 – 128.

Primadani, R. G., 2023, Kesesuaian Terapi Pada Pasien Penyakit Paru Obstruktif Kronis Rawat Jalan di RS Khusus Paru Respira Yogyakarta, *Skripsi*, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta

Putri, N., Khairisyaf, O., Medison, I., Sabri, Y., Pulmonologi, B., Respirasi, K., Kedokteran, F., & Andalas, U. (2016). Hubungan Derajat PPOK dan Kejadian Eksaserbasi pada Penderita PPOK dengan Komponen Sindrom Metabolik Degrees Relations & Event Exacerbations COPD Patients with Components of Metabolic Syndrome. *J Respir Indo*, 36(1).

Ramakrishnan, S. (2023). Prednisolone for COPD exacerbations: time for a rethink. *ERJ Open Research*, 9(5), 00464-2023. <https://doi.org/10.1183/23120541.00464-2023>

Ramos, F. L., Krahne, J. S., & Kim, V. (2014). Clinical Issues of Mucus Accumulation in COPD. *International journal of chronic obstructive pulmonary disease*, 9, 139–150. <https://doi.org/10.2147/COPD.S38938>

Ratini, M., 2023, Life Expectancy with COPD, <https://www.webmd.com/lung/copd/features/copd-life-expectancy>, diakses pada 03 Januari 2024.

Roberts, M., Mapel, D., Petersen, H., Blanchette, C., dan Ramachandran, S., 2011, Comparative Effectiveness of Budesonide/Formoterol and Fluticasone/Salmeterol for COPD Management, Vol. 14, No. 6, Hal : 769 – 776.

Rogliani, P., Matera, M. G., Page, C., Puxeddu, E., Cazzola, M., & Calzetta, L. (2019). Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. *Respiratory Research*, 20(1). <https://doi.org/10.1186/s12931-019-1078-y>

Sangroula, P., Ghimire, S., Srivastava, B., Adhikari, D., Dhonju, K., Shrestha, A., & Ghimire, S. (2023). Correlation of Body Mass Index and Oxygen Saturation in Chronic Obstructive Pulmonary Disease Patients at a Tertiary Care Center in Nepal: A Cross-Sectional Study. *International journal of chronic obstructive pulmonary disease*, 18, 1413–1418. <https://doi.org/10.2147/COPD.S412118>

Sethi, S. (2010). Infection as a comorbidity of COPD. *European Respiratory Journal*, 35(6), 1209–1215. <https://doi.org/10.1183/09031936.00081409>

Shin, S. H., Kwon, S. O., Kim, V., Silverman, E. K., Kim, T.-H., Kim, D. K., Hwang, Y. I., Yoo, K. H., Kim, W. J., & Park, H. Y. (2022). Association of body mass index and COPD exacerbation among patients with chronic bronchitis. *Respiratory Research*, 23(1). <https://doi.org/10.1186/s12931-022-01957-3>

Siddiqi, A., & Sethi, S. (2008). Optimizing antibiotic selection in treating COPD exacerbations. *International journal of chronic obstructive pulmonary disease*, 3(1), 31–44. <https://doi.org/10.2147/copd.s1089>

Smulders, L., van der Aalst, A., Neuhaus, E. D. E. T., Polman, S., Franssen, F. M. E., van Vliet, M., & de Kruif, M. D. (2020b). Decreased Risk of COPD Exacerbations in Obese Patients. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 17(5), 485–491. <https://doi.org/10.1080/15412555.2020.1799963>

Somayaji, R., dan Chalmers, J.D., 2022, Just Breathe: a Review of Sex and Gender in Chronic Lung Disease, *European Respiratory Review*, Vol. 31, No. 163, Hal : 1 – 17.

Sonetti, D. A., Hospenthal, A. C., & Adams, S. G. (2010). Integrated management strategies for chronic obstructive pulmonary disease. *Journal of multidisciplinary healthcare*, 3, 181–188. <https://doi.org/10.2147/JMDH.S8173>

Suissa, S. (2023). Triple therapy in COPD: understanding the data. *ERJ Open Research*, 9(1), 00615-2022. <https://doi.org/10.1183/23120541.00615-2022>

Tashkin, D.P., 2020. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis*, 15: 3105–3122.

Thu, P. N. T., Huong, M. N. T., Thi, N. T., Thanh, H. N., & Minh, K. P. (2021). Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial. *BMC Infectious Diseases*, 21(1). <https://doi.org/10.1186/s12879-021-06687-3>

Vézina F.A., dan Cantin, A.M., 2018, Antioxidants and Chronic Obstructive Pulmonary Disease, Vol. 5, No.4, Hal : 277 – 288.

Vollenweider, D. J., Frei, A., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A. (2018). Antibiotics for exacerbations of chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*, 10(10), CD010257. <https://doi.org/10.1002/14651858.CD010257.pub2>

Wang, Y., Li, Z., & Li, F. (2023). Impact of Previous Pulmonary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study. *Combinatorial chemistry & high throughput screening*, 26(1), 93–102. <https://doi.org/10.2174/1386207325666220406111435>

Wang, Z., Li, Y., Lin, J., Huang, J., Zhang, Q., Wang, F., Tan, L., Liu, S., Gao, Y., Peng, S., Fang, H., Weng, Y., Li, S., Gao, Y., Zhong, N., dan Zheng, J., 2023, Prevalence Risk Factors, and Mortality of COPD in Young People in the USA: Result from a Population-Based Retrospective Cohort, *BMJ Open Respiratory Research*, Vol. 10, No.1, Hal : 1 – 9.

Weir, C.B., dan Jan, A., 2023, BMI Classification Percentile and Cut Off Points, <https://www.ncbi.nlm.nih.gov/books/NBK541070/> diakses pada 03 Januari 2024.

Welte, T., Miravittles, Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., dan Kessler, R., 2009, Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease, *American Journal of Respiratory and Critical Care Medicine*, Vol. 180, No.8, Hal : 741 – 750.

Westerik, J. A., Metting, E. I., van Boven, J. F., Tiersma, W., Kocks, J. W., & Schermer, T. R. (2017). Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. *Respiratory research*, 18(1), 31. <https://doi.org/10.1186/s12931-017-0512-2>

Whittaker, H., Rubino, A., Müllerová, H., Morris, T., Varghese, P., Xu, Y., De Nigris, E., & Quint, J. K. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. *International journal of chronic obstructive pulmonary disease*, 17, 427–437. <https://doi.org/10.2147/COPD.S346591>

Williams, D.M., 2018, Clinical Pharmacology of Corticosteroids, *Respiratory Care*, Vol. 63, No.6, Hal : 655 – 670.

Woodhead, M. (2005). Guidelines for the management of adult lower respiratory tract infections. *European Respiratory Journal*, 26(6), 1138–1180. <https://doi.org/10.1183/09031936.05.00055705>

Woods, J. A., Wheeler, J. S., Finch, C. K., & Pinner, N. A. (2014). Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. *International journal of chronic obstructive pulmonary disease*, 9, 421–430. <https://doi.org/10.2147/COPD.S51012>

World Health Organization. (2023, March 16). *Chronic obstructive pulmonary disease (COPD)*. World Health Organization: WHO. [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))

Yakar, H. I., Gunen, H., Pehlivan, E., & Aydogan, S. (2017). The role of tuberculosis in COPD. *International journal of chronic obstructive pulmonary disease*, 12, 323–329. <https://doi.org/10.2147/COPD.S116086>

Yazar E, Sahin F, Aynaci E, Yildiz P, Ozgul A, Yilmaz V. s there any relationship between the duration to diagnosis of COPD and severity of the disease? *Eur Respir J*. 2012:739.

Yulianti, E., 2022, Pengaruh Pemberian Inhalasi Budesonid 160 mcg/Formoterol Fumarat 4,5 mcg Turbuhaler dibandingkan dengan Flutikason Propionat 250 mcg/Salmeterol Xinafoat 50 mcg Diskus Pada Rehospitalisasi Pasien PPOK (Penyakit Paru Obstruktif Kronik) Setelah Rawat Inap di Rumah Sakit Paru Respira, *Tesis*, Universitas Gadjah Mada, Yogyakarta.

Zheng, Y., Zhu, J., Liu, Y., Lai, W., Lin, C., Qiu, K., Wu, J., & Yao, W. (2018). Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. *BMJ*, k4388. <https://doi.org/10.1136/bmj.k4388>